The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its subsidiary company Medical Cannabis Limited (MCL) through its wholly owned subsidiary Medical Cannabis Research Group Pty Ltd (MCRG), has signed a Research Funding Agreement with the Research & Development Foundation at the Technion Institute, Haifa, Israel. The agreement revolves around the research of Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion Institute.

Cannabis as a Potential Therapy for Multiple Sclerosis

According to the agreement MCRG will sponsor the continued Research of how the cannabis plant can be used for the treatment of Multiple Sclerosis (MS). Prof. Meiri has identified the synergistic relationship between the Cannabis plant and the human genome that will form the basis for this research.

Highlights

- Medical Cannabis Ltd (MCL) a subsidiary of Queensland Bauxite Limited (ASX:QBL), completes an arrangement to sponsor research into medical cannabis treatments for Multiple Sclerosis (MS).

- MCL through its Medical Cannabis Research Group Pty Ltd (MCRG) has signed an agreement with the Technion Research & Development Foundation for the performance of research by Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion - Israel Institute of Technology in Haifa, Israel. Prof. Meiri is Head of the Technion's Cannabis research team. According to the agreement, MCRG will sponsor research into how the cannabis plant can be used in the treatment of symptoms and halting the progression of autoimmune diseases with special emphasis on Multiple Sclerosis (MS).

- Long-standing and approved MS treatments can reduce relapses, but current solutions may slow down, but ultimately do not arrest the progression of the disease.

- The overall objective of Prof. Meiri's study is to identify specific cannabis compounds that can be used in clinical trials as a potential treatment for Multiple Sclerosis (MS).

- MCL through its Medical Cannabis Research Group (MCRG) will agree to fund Research into Prof. Meiri's study in return for an exclusive license for any product derived from the Research.

- Should a successful product eventuate, the Board believes, in time, this Research has the potential to be a global medical 'game changer' for MS sufferers, and a material revenue stream for MCL.

- MCRG has committed to fund USD$3M over a 3-year period, towards the research budget, in return for an exclusive license of any product to be developed from this research for MS, or potentially for any product that could alleviate or treat any other auto immune disease that could be developed from this research.

Pnina Feldman, Executive Chairperson of QBL says: "The Boards of QBL and MCL feel privileged to be working with Prof. Meiri and his team of medical cannabis researchers at the Technion-Israel Institute of Technology, not only for the opportunity to be in with top researchers who are one of the leaders in the world with this research, and not only to commercialise the products that may result from this research, but for this unique and ground-breaking opportunity to work diligently towards the betterment of health worldwide. Everyone knows someone with an- autoimmune disease in one form or another, and there could be no more satisfying outcome, or more important work, than making the lives of these people not only easier, but hopefully enabling respite from symptoms and cures for disease. The benefits of the age-old cannabis plant, combined with state of the art medical technology, is opening new horizons, and we are both proud and humbled to be amongst the pioneers supporting and being a part of this amazing research."

Assistant Professor, Heads the "Laboratory of Cancer Biology and Cannabinoid Research", Technion, Israel Institute of Technology, Israel.

David (Dedi) Meiri, PhD, is an Assistant Professor at the Faculty of Biology at the Technion Israel Institute of Technology and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri's scientific background is highly diverse. He holds a M.Sc. in biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he expanded his knowledge in human biology and cancer pathogenesis and focused on the role of the GEF-H1 protein in tumor invasion and metastasis. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the "Laboratory of Cancer Biology and Cannabinoid Research".

Presently, his lab investigates the therapeutic potential of phytocannabinoids, the unique active compounds of the Cannabis sativa plant. On top of other research being conducted in the lab, the main focus of his research is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects of phytocannabinoids.

From the establishment of his lab it has grown significantly and it is now comprised of 38 scientists; a highly trained team of skilled plant biologists, chemists, cancer experts and neuroscientists who work together in synergy to complement one another in order to achieve the highest level of results. Dr. Meiri's lab, is one of the leading laboratories in the world that is exceptionally equipped with the capabilities and resources to ask and answer almost any question in the field of medical cannabis.

Dr. Meiri operates the "Cannabis Database Project" and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment, such as: colon disease, pain prevention, cancer treatment and epilepsy. He collaborates with cannabis growers, clinicians and major manufacturers and distributors of medical cannabis, including Andrew Kavasilas from QBL: MCL in the purpose of revolutionizing cannabis treatment.

Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees which seek to advance the fundamental understanding of optimal cannabis usage and minimization of adverse side effects.

Background - Technion Israel Institute of Technology

Technion - Israel Institute of Technology was founded in 1912 in Haifa and is the oldest university in Israel The Institute is currently rated #93 in the World's Top 500 Universities and is the only Israeli university in the top 100 of the list. (2017 - Shanghai Ranking World Leading Universities)

Technion researchers, including three Nobel laureates in chemistry, have won many International awards for their research in the fields of Microbiology, Microbial Diagnostics, Genomics, Antibiotics to name just a few. Technion people, ideas and inventions make immeasurable contributions to the world including life-saving medicine, sustainable energy, computer science, water conservation and nanotechnology.

Technion is widely recognized as a global leader in Medical Cannabis Research. Israel has been leading the world since the early 1960's in Medical Cannabis research.

In November 2017, Times Higher Education ranked Technion as the world's leading academic institution in teaching digital skills to students, ahead of the prestigious American M.I.T. University.

Background - Autoimmune disease

The Australian Society of Clinical Immunology and Allergy (ASCIA) states that autoimmune diseases affect around 5% of people and are one of the most important health issues in Australia and New Zealand.

An autoimmune disease is a disease in which the body's immune system attacks healthy cells. The most common types of autoimmune diseases include:

- Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.

- Lupus: An inflammatory disease caused when the immune system attacks its own tissues.

- Celiac Disease: An immune reaction to eating gluten, a protein found in wheat, barley and rye.

- Multiple Sclerosis: A disease in which the immune system eats away at the protective covering of nerves. This condition can last for years or be lifelong. In MS resulting nerve damage disrupts communication between the brain and the body.

- Type 1 Diabetes: A chronic condition in which the pancreas produces little or no insulin.

- Other diseases include: Sjogren's syndrome, Polymyalgia rheumatica, Ankylosing spondylitis, Alopecia areata, Vasculitis, Temporal arteritis, Crohn's disease, Graves disease (thyroid) etc. In all, there are 80 known autoimmune diseases, with an estimated 50 million Americans suffering these diseases in increasing numbers. The disorders range in severity from mild to disabling, depending on which system of the body is under attack and to what degree.

The causes of autoimmune diseases are unknown. In many cases it appears that there is some hereditary tendency. However, other factors such as injections and some drugs may play a role in triggering autoimmune diseases.

No Known Cure

Autoimmune disorders in general have no known cure, but the conditions can be somewhat controlled and managed in many cases.

Treatments

Historically, treatments include:

- Anti-inflammatory drugs - to reduce inflammation and pain.

- Corticosteroids - to reduce inflammation. They are sometimes used to treat an acute flare of symptoms.

- Pain-killing medication - such as paracetamol and codeine.

- Immunosuppressant drugs - to inhibit the activity of the immune system.

- Physical therapy - to encourage mobility.

- Treatment for deficiency - for example insulin injections in the case of diabetes.

- Surgery - for example to treat bowel blockage in the case of crohn's disease.

- High dose immunosuppressants - the use of immune system suppressing drugs (in the doses needed to treat cancer or to prevent the rejection of transplanted organs), have been tried recently, with promising results. Particularly when intervention is early, the chance of a cure with some of these conditions seems possible.

- Stem cell Research - Recent experimentation in Israel with stem cell implanting to treat impaired bodily functions is being trialled and although very invasive is showing some progress.

The goal of the cannabis research in the field of auto immune disease is to find a treatment and possible cure that does not have the serious side effects of other treatments being researched or used to date.

The Role of Cannabis in Autoimmune Diseases

So far, the approved and available treatment for autoimmune diseases with medicinal cannabis, has been in the area of pain relief, the cannabis formula replacing morphine and its derivatives, with morphine in high and frequent doses being serviceable mainly in palliative care. The medicinal cannabis pain relief available for (MS) for example, is most effective in relieving pain, enabling sufferers to function better without the side effects of pain relieving drugs such as morphine. The danger of morphine has been recognized by the Australian authorities, who as of February 1, 2018 requires codeine to be a prescription only drug.

Andrew Kavasilas, Technical Director of MCL, said: "This is a very logical avenue of research, especially when the only semi-legal Cannabis medicine in the world was developed for the treatment of MS. That was a first wave cannabinoid medicine and a vast amount of knowledge has been gained since then. There's an incredible amount of work being done in Israel which has capitalised on many opportunities due to their government's willingness to allow medical Cannabis use by well over 100 000 people, while the profession scientific research catches up to break down all this valuable evidence".

Dr David (Dedi) Meiri - Cannabis as a Potential Therapy for Multiple Sclerosis

Due to the legal access to medical researchers and doctors of high and low THC Cannabis plants under the auspices of the Israeli Health Department, Israel is currently at the forefront of medicinal cannabis research, and the world-renowned Dr Meiri is arguably today's leading medicinal cannabis researcher in Israel, if not in the world.

Dr Meiri is head of the Technion's Cannabis Research team and will be the principal investigator in research to be funded by MCRG (the research and wholly owned subsidiary company of MCL). Dr Meiri lectures and teaches about the latest developments in cannabis research throughout the world, and has recently been on a lecture tour to Australia, speaking in Sydney at a function organized at Wolper hospital for doctors interested in Dr Meiri's new and exciting research insights.

Assisting Dr Meiri's team of close to 30 researchers, will be supporting investigators Dr Igal Louria-Hayon PhD and Dr Gil Lewitus PhD.

Overall Objective

The overall objective of Dr Meiri's study is to match effective cannabis extracts and specific cannabinoids composition that regulate/modulate immune function, specifically, autoimmunity in MS in order to optimize treatment for MS patients.

It is hoped that achieving a successful outcome of the overall objective could lead to a possible cure for MS through the strengthening of the immune system, which in turn will assist the research into other auto immune diseases and diseases in general.

Dr Meiri Comments:

"Although current treatment of MS with broad-spectrum immunomodulatory drugs reduces immune cell activity and entry into the central nervous system (CNS) and decreases relapse frequency, they are often associated with side effects, ranging from flu-like symptoms to the development of other auto-immune disorders; fatal opportunistic infections such as progressive multifocal leukoencephalopathy; and other malignancies.

"These side effects highlight the need to identify more specific therapeutic targets that can be effectively modulated without inducing such adverse reactions. In addition, it is increasingly acknowledged that although the long-standing and approved MS treatments can reduce relapses, they do not ultimately halt the disease. Therefore, neuroaxonal damage, which results in progressive physical disability, continues to accumulate and becomes permanent throughout the disease progression.

"Recently, the therapeutic potential of phytocannabinoids, the unique active compounds of the cannabis plant, has been discovered in the area of immunology; More than 140 phytocannabinoids have been identified within the cannabis plant. A few specific natural and synthetic cannabinoids have been proposed to have therapeutic potential for various diseases. The U.S. Food and Drug Administration (FDA) recently approved the use of several synthetic cannabinoids to be available by prescription for pain relief treatment.

"Cannabinoids have been largely characterized for their action in the immune system and were tested in several in vitro and in vivo disease models for inflammation (a common symptom of numerous autoimmune diseases). Recent research showed that administration of tetrahydrocannabinol (THC) with mice triggered significant caspase medicated cell death in T cells and dendritic cells, resulting in immunosuppression. In addition, other research demonstrated that cannabinoids downregulate cytokine and chemokine production and at times upregulate T regulatory cells as a mechanism to suppress inflammatory responses. The targeted actions of cannabinoids in the endocannabinoid system is also involved in immunoregulation.

"CDB another abundant cannabinoid was found to exhibit a suppressive effect on T cell functional activities via reducing IL-17 cytokine secretion, a key autoimmune factor which was also shown to be involved in multiple sclerosis (MS). In this context, its additional neuroprotective effects, which included the upregulated of a number of anti-oxidative genes (e.g. those of glutathione synthesis) in CBD exposed microglial cells from inflammation-induced apoptosis may significantly enhance its anti-inflammatory beneficial properties and account for alleviation of MS pathology.

"As of now, there are several different cannabinoid medications approved for patients with MS, inducing cannabis in its natural form. Cannabis is primarily used to reduce muscle stiffness and pain. However chemical trials to date done with specific cannabinoids showed small or no effect on disease progression from the above current cannabinoid medications.

"Other compounds in Cannabis have been poorly studied regarding their potential immunosuppressive effects. For example, it has been shown that terpenoids are key components of cannabis activity as they are known to participate in making the plant extract more potent than synthetic cannabinoids. Overall, Cannabis's multiple inflammatory effects on various immune cell types, together with the vast number of phytocannabinoids and different ratios of cannabinoids in different strains makes the Cannabis plant a complex matrix with great therapeutic potential.

"Cannabis chemical composition analyses currently focus on identifying and qualifying and quantifying several major Cannabinoid types including THC, CBD, and in some recent studies also cannabichromene (CBC), cannabinol (CBN), and cannaligerol (CBG). Other Cannabis compounds which may be important for their therapeutic effects, have predominantly been neglected.

"In order to identify more cannabinoid types, we developed, in our lab, a novel ability to analyze the metabolomics and the specific chemical composition of cannabis plants.

"As far as we know, 'WE ARE THE ONLY LAB IN THE WORLD TODAY THAT HAVE THESE ABILITIES OF COMPREHESIVELY PROFILING THE CANNABINOID COMPOSITION FOR A VARIETY OF CANNABIS STRAINS AND ALSO TO BE ABLE TO PURIFY SINGLE PHYTO-CANNABINOIDS AND CREATE "SUSPECT PROFILES" FOR EXAMINATION IN DIFFERENT TYPES OF STUDIES.'

Research Plan

"In the last year, we established the novel ability to analyze the metabolomics and the specific chemical composition of Cannabis plants (principally of phytocannabinoids and terpenes). We intend to identify the effects of different cannabinoids and terpenes both individually and in combination on the function of immune cells, specifically on MS-derived autoimmune and regulatory cells in vitro. We intend to evaluate the immunomodulatory properties of specific cannabinoid extracts in in vivo rodent models of MS. This will enable us to detect the most effective extracts in in vivo rodent models of MS. This will enable us to detect the most effective Cannabis extract and cannabinoid profiles for regulating immunopathology in MS.

Specific Aims

- Characterize clinically-used Cannabis strains using comprehensive mass-spectrometry based metabolomics.

- Screen for the immunoregulatory properties of different Cannabis extracts on immune cell function and MS immunopathology.

- Demonstrate the immunomodulatory properties of specific Cannabis extracts on various MS rodent models and identify specific compounds that can then be used in clinical trials as potential treatment for MS.

Significance

"Affecting millions of people worldwide, Multiple Sclerosis (MS) is the most common autoimmune disorder affecting the central nervous system. Therapies for MS are only partially effective and there is no known cure. Therefore, there exists a great and unmet clinical need for the development of neuroprotective treatments. Today, MS patients are treated with medical Cannabis primarily for the palliative purposes. Furthermore, the specific Cannabis strain for palliative treatment is chosen arbitrarily. Consequently, evaluating the immunomodulatory properties of Cannabis in MS and tailoring the best combination of phytocannabinoids may open new treatment possibilities for MS patients with the intention of finding a cure."

Summary

"In this work we aim to elucidate the immunoregulatory properties of phytocannabinoids and terpines in MS, as well as further investigate Cannabis's mechanisms of action in these areas. This research not only has the ability to advance the identification of new drug candidates, but also advance our abilities to optimize Cannabis treatment options and efforts towards the creation of personalized medicine for MS patients."

Pnina Feldman, Executive Chairperson and Director of Business Development of QBL stated: "Having had the pleasure of meeting Dr David Meiri at the Wolper Doctors Conference, in Australia, in June 2017, I was very happy for the opportunity to open a dialogue with Dr Meiri, which was the beginning of this current deal. We are very excited about the work being carried out by Dr Meiri, and his team at Technion, and we believe that this research will hopefully be of major benefit worldwide, and in particular to QBL shareholders who support our ground-breaking work."

To view figures, please visit:
http://abnnewswire.net/lnk/4V8V11WC

Queensland Bauxite Ltd
Tel: +61-2-9291-9000

For further information or any queries please email the Company at:
sfeldman@queenslandbauxite.com.au

Goldfields Money (ASX:GMY) has returned to profitability in H1 FY18 with a statutory profit after tax of $62,707 and an underlying profit after tax of $362,638.

Summary of H1 FY18

- H1 FY18 marked a return to profitability for Goldfields Money Limited ("Goldfields Money" or the "Company") with a statutory profit after tax of $62,707 and an underlying profit after tax of $362,638 (after accounting for transaction costs incurred in relation to the Firstmac takeover offers and proposed Finsure merger)

- The Company continued growth of its loan portfolio and delivery of the new core banking platform to enhance Goldfields Money's digital banking capabilities. This project is currently at an advanced stage of implementation and the new platform is expected to "go live" in the coming weeks

- A record of $23.8 million new loans were settled in H1 FY18 with total loans under management increasing to $200.5 million, which is reflective of the Company's investment in developing and expanding distribution capabilities

- Major shareholder Firstmac made an unsolicited takeover offer for Goldfields Money in H1 FY18, initially offering $1.12 per share and later increasing the offer to $1.27 per share, which the Directors recommended that shareholders reject. Firstmac's offer expired without a single share being sold to them

- In November 2017, the Company announced a proposed merger with Finsure, with Goldfields Money shares to be valued at an attractive issue price of $1.50 per share to Finsure. Both Goldfields Money and Finsure continue to progress the proposed merger, which aligns with the Company's strategy of building distribution and origination capabilities via a broker led distribution strategy

To view the full presentation, please visit:
http://abnnewswire.net/lnk/4WMDI5GY

To view the Half Year Report, please visit:
http://abnnewswire.net/lnk/7NQT3I96

Investor / Media Enquiries
Simon Lyons
Executive Director & CEO
Goldfields Money
slyons@goldfieldsmoney.com.au
M: +61-417-178325

Further to the ASX announcement dated 19th February 2018, the Board of TopBetta Holdings Limited (ASX:TBH) ("TopBetta" or the "Company") is pleased to announce that the Company has completed the issue and allotment of 3,508,771 fully paid ordinary shares ("Placement Shares") to raise AUD$1M at 28.5 cents per Placement Share from sophisticated and institutional investors ("Placement").

The Placement Shares have been issued without disclosure under the Company's placement capacity under ASX Listing Rule 7.1.

Further to the ASX announcement dated 9th October 2017, the Company wishes to advise that Modern Wagering Systems Pty Ltd ("MWS") has satisfied it's training and support obligations in respect of the software code base of the Global Tote. Accordingly, the Company has released the voluntary escrow restrictions applicable to 1.25M of MWS' shares with effect on and from today.

MWS continues to be an avid supporter of the Company and remains a shareholder of TBH.

Charly Duffy
Company Secretary
E: companysecretary@topbetta.com
M: + 61-409-083-780

Jane Morgan
Investor & Media Relations
E: investors@topbetta.com
M: +61-405-555-618

Revolution Metals Ltd is pleased to announce that the Kirkby Jones Financial Group has been appointed as Company Auditor.

The Group, based in Sydney, is a member of the Institute of Chartered Accountants in Australia (the Institute).

The contact details are:

KIRKBY JONES FINANCIAL GROUP
Suite 607 20 Bungan Street
MONA VALE NSW 2103

Ph Office: +61 2 9979 7811
Fax: +61 2 9979 7822
Web: www.kirkbyjones.com.au

Revolution Metals Ltd
Tim Mckinnon
T: +61-2-8205-7339
WWW: www.revolutionmetals.com

The Directors present their report on the consolidated entity consisting of Central Petroleum Limited (ASX:CTP) (OTCMKTS:CPTLF) and the entities it controlled at the end of, or during, the half-year ended 31 December 2017.

Principal Activity

The principal continuing activity of the consolidated entity ("the Group") during the period was the exploration, development and production of hydrocarbons.

Highlights for the half-year reporting period and up to the date of this report
Commentary and Outlook

- Operating revenue increased by 39.8% over the previous corresponding period from $12.6million to $17.7 million.

- Gas sales volumes increased 50.6% over the previous corresponding period, reflecting gas sold under the EDL NGD (NT) Pty Ltd ("EDL") Gas Supply Agreement ("GSA") which commenced in June 2017.

- Earnings before Interest, Taxes, Depreciation, Amortisation and Exploration Expenses ("EBITDAX") for the Producing Assets segment increased by 81.7% over the previous corresponding period from $4.8 million to $8.7 million.

- The Company successfully completed a fully underwritten institutional and sophisticated investor placement of shares and a fully underwritten traditional non-renounceable entitlement offer, at an issue price of A$0.10 per share, raising $25.5 million (net of costs).

- The consolidated entity held cash balances totalling $28.6 million at 31 December 2017.

- Testing of the Stairway Sandstone at Mereenie from the previously drilled West Mereenie 15 continued free flowing gas at sustainable rates with a low nitrogen content of 2.6%. Additional recompletion opportunities have been identified.

- Dr Sarah Ryan, Mr Martin Kriewaldt and Mr Tim Woodall joined the Central Board as independent Non-executive Directors as part of the Company's commitment to augment and strengthen the current Board.

This half-year reflects a full 6 months of gas delivered under the EDL GSA, with a pleasing continuation of prudent cost control leading to improved operating cash flow and profit performance.

The Company successfully completed an Equity Raising to support it Gas Acceleration Programme with the objective of substantially increasing its gas reserves in time to have delivery coincide with the Northern Gas Pipeline ("NGP") becoming operational in late 2018.

The various pipeline regulation reviews and reforms continue to take shape with several key reforms being implemented over the next year, including Day Ahead Auction, binding arbitration for non-scheme pipelines, and a review into the National Gas Laws for covered pipelines. Central remains optimistic that these reforms will put downward pressure on transportation costs and thereby facilitating our ability to sell new gas supply into the east coast market following commencement of the Northern Gas Pipeline later this year.

The Mereenie Joint Marketing Agreement ("JMA") between the Mereenie Joint Venture participants was announced on 25 September 2017 and remains subject to approval from the ACCC. We anticipate a decision from the ACCC could be made later this month.

Since the end of the current reporting period the Company announced it has signed a contract with Ensign Australia Pty Ltd for the forthcoming drilling programme of up to four wells, structured commercially as two required wells and an option for up to two further wells. Joint Venture approval of Mereenie wells is subject to ACCC interim clearance of joint marketing.

To view the full report, please visit:
http://abnnewswire.net/lnk/7RK0G9DQ

Central Petroleum Limited
T: +61-7-3181-3800
F: +61-7-3181-3855
E: info@centralpetroleum.com.au
WWW: www.centralpetroleum.com.au

The Board of ARBITRADE is pleased to announce that the role of the Chairman of the Board of Directors, Leonard Schutzman, has been expanded to Chief Executive Officer.

Mr. Schutzman had a distinguished thirty-year career at PepsiCo, Inc., serving in a variety of leadership positions including Treasurer of PepsiCo Corporate, and Chief Financial Officer of Pepsi Cola International, Frito-Lay and Taco Bell

Commenting on his appointment, Mr. Schutzman said he was excited to take on this leadership role in an industry that will grow exponentially on a global scale. "It is a time of growth for our companies and at Arbitrade, I am fortunate to be supported by some of the best minds in the Cryptocurrency. This, and the combination of our distinctive strategy and proprietary software, will allow me to put together a world class management team and Board of Directors. I am confident that Arbitrade has the potential to be a best-of-breed Cryptocurrency company."

ARBITRADE, through its proprietary software and strategic partnerships, plans to be in all segments of the cryptocurrency business, including currency mining, trading (The ARBITRADE Exchange) gift cards, debit cards, money transfer and Point of Sale processing.

For more information, visit:
http://www.arbitrade.io

Victor Webb
Marston Webb International
T: (212) 684-6601, C: (917) 887-0418	
e-mail: marwebint@cs.com

MMJ PhytoTech Limited (ASX:MMJ) ("MMJ" or "the Company") is pleased to attach an investor presentation and speaker notes to be presented by the Company's Chief Executive Officer Jason Conroy today in Sydney at the Finance News Network Investor Event.

Speaker Notes

Good morning.

My name is Jason Conroy and I am, as of yesterday, the new CEO of MMJ.

As we announced on 19 February, I have replaced Andreas Gedeon who has retired as CEO and Managing Director to devote his time and energy to growing Harvest One, which is currently MMJ's largest investment.

I am new to the cannabis sector.

My most recent experience was as CFO of an ASX100 group where I managed a portfolio of energy infrastructure companies for nine years.

As part of that role I was responsible for M&A, recapitalisations and restructuring which led to the group being acquired at an attractive valuation.

So I definitely bring a new perspective and set of skills to managing and building MMJ's portfolio of investments.

With this fresh set of eyes I am very excited to lead MMJ into the next phase of its growth.

So turning now to the presentation and we start on slide 2.

Slide 2: Investment Strategy

MMJ's investment strategy is clear.

We are focused on building a diversified portfolio of cannabis sector investments.

MMJ owns a portfolio of five investments and we see scope to further grow and develop this portfolio over the next few years.

We differentiate ourselves from a number of other ASX listed entities in the sector by focusing our attention on Canada.

Why? Because Canada is expected to legalise its recreational market in mid to late this year, opening up a potential multi billion-dollar market opportunity for companies like those in MMJ's portfolio.

Similar to a private equity investor, we will take an active management approach to exiting, merging or diluting ownership positions where it adds value for our shareholders.

Our future focus is to create opportunities for MMJ's shareholders to benefit from our due diligence and participate in the growth of a diversified group of privately held minority investments.

My background and experience, complemented by the corporate finance and legal experience of MMJ's board, positions us well to capture, manage and optimise future investment opportunities.

Slide 3: Current Investment Portfolio

MMJ's investment portfolio is summarised on slide 3.

Our investments are diversified across the cannabis value chain.

The core investment in our portfolio is Harvest One, a TSX-V listed company in which MMJ holds over 53 million shares representing a significant minority shareholding of around 34%.

With recent capital raisings, Harvest One has a cash balance of around C$80 million to fund its growth initiatives with a focus on expanding its cannabis production facilities.

MMJ is satisfied with the level of its investment in Harvest One and expects its shareholding to be progressively diluted as Harvest One raises capital in the future to fund growth initiatives and as various convertible instruments are exchanged for ordinary shares.

WeedMe and Dosecann are MMJ's most recent investments, with each focused on the Canadian market.

With WeedMe we are aiming to replicate the business model and success of Harvest One.

With Dosecann we are backing an experienced management team that is focusing on extraction facilities and on developing new products.

I aim to present and discuss the outlook of MMJ's investments in more detail once I have met each of the management teams in the next few months.

Slide 4: Canadian Market Opportunity

I am now on slide 4.

As I have already mentioned, we see Canada as a very attractive market for MMJ's investments.

Canada is expected to be the largest federal jurisdiction in the world to legalise cannabis consumption.

The total legalised market opportunity is estimated by Deloitte to exceed $20 billion.

Moving to slide 5.

Slide 5: Canadian Licensed Producers

In my opinion, one of the most fascinating and exciting developments is the level of Canadian public market investor interest in the sector and the emergence of consolidation by the larger players.

Looking at the table, on a comparable basis we see significant upside from our investment in Harvest One as it moves to deliver its funded capacity.

Slide 6: Contact Details

That concludes my presentation and I thank you for your attention and interest in MMJ.

To view the presentation, please visit:
http://abnnewswire.net/lnk/5PH8ZR91

Investor Enquiries:
Jason Conroy
Chief Executive Officer
E: info@mmjphytotech.com.au

Media Enquiries:
Sam Burns
Six Degrees Investor Relations
M: +61-400-164-067

OtherLevels Holdings Limited (ASX:OLV) ("OtherLevels") has announced that it has expanded its partnership with a major European customer, and signed a multi-year contract with a baseline value in excess of A$2.25m. Over $2m of the contract consists of licence fees.

The contract includes a core set of OtherLevels products, including 4 message types, and is for a 4 and a half year term. From the second year additional fees for further messages; additional message formats and modules, together with professional services, are likely. The baseline fee is paid as an upfront payment at the start of the contract, with 4 further annual payments.

During the next 12 months, the OtherLevels team will work with the customer to complete the deployment of app push, web push, interstitials and rich inbox message types across desktop web, mobile web and app. OtherLevels digital marketing strategists will also work with the customer building messaging strategies to drive increased registration activity, and helping turn unknown site visitors into known users. OtherLevels' detailed attribution capability means that the customer is able to directly measure increased conversion and engagement.

Brendan O'Kane, the OtherLevels Managing Director, commented "We are very pleased to expand this existing partnership. This is a strong endorsement of the value that OtherLevels brings, and also demonstrates confidence in OtherLevels ability to innovate and maintain leadership in the digital messaging space".

O'Kane added "OtherLevels goal is to be the digital messaging partner of choice for all of our customers. Having a deep understanding of our customer's needs, lets us build win/win partnerships, and establishes the basis for mutually beneficial long term relationships."

Media Enquiries
E: media@otherlevels.com
WWW: www.otherlevels.com

Prospect Resources (ASX:PSC) has established a laboratory complex in the Kwekwe area which is now fully functional and supporting the laboratory scale and pilot scale production of lithium carbonate.

Highlights:

- Commissioning commences at Prospect Resources' battery grade lithium carbonate pilot plant in Kwekwe, Zimbabwe

- Small scale production of Battery grade >99.5% lithium carbonate continues in Prospect Resources' laboratory, Kwekwe, Zimbabwe

- Ramp up to full pilot production rate of over 100 kg per month of battery grade lithium carbonate expected during Q2 2018

The laboratory achievements to date include:

- Recruitment and training of a team of assayers, chemists and engineers;

- Developed an in-house capacity for metallurgical test work including flotation and leaching test work;

- Full implementation of a laboratory scale lithium carbonate production process to demonstrate the amenability and viability of converting Arcadia 4% Li2O Petalite concentrates into battery grade lithium carbonate.

The company is delighted to announce these results, which demonstrate the success of the programme. In response to these results, Mr Hugh Warner (Chairman) had the following to say: "This is a significant achievement for both Prospect Resources and Zimbabwe. Producing high grade battery quality lithium carbonate that exceeds industry norms bodes well for the ultimate company goal of a large scale lithium carbonate facility in-country. This entire process has been designed and built in-country using local skills and services further demonstrating the business friendly environment that Zimbabwe is rapidly becoming."

To view figures, please visit:
http://abnnewswire.net/lnk/6PJ373ZY

Hugh Warner
Prospect Resources Ltd
Executive Chairman
T: +61-413-621-652

Harry Greaves
Prospect Resources Ltd
Executive Director
T: +263-772-144-669
WWW: www.prospectresources.com.au

White Rock Minerals Ltd (ASX:WRM) ("White Rock" or the "Company") is pleased to provide an update on its plans to conduct a comprehensive exploration program at its globally significant 100% owned zinc VMS project at Red Mountain in Alaska.

White Rock announced its exploration strategy for Red Mountain in December last year (refer ASX Announcement dated 18 December 2017 "WRM - Exploration Program Planned - Red Mountain Zinc Project"). This strategy is focused on: -

- A targeted diamond drilling program aimed at in-fill and expansion of the high grade maiden Resource,

- On-ground orientation EM and possibly geochemistry exploration across the two already identified deposits,

- Regional application of the best geophysics and geochemistry exploration tools determined from the on-ground orientation work, and

- A follow-up diamond drilling program on the best of the more than 30 already identified exploration targets.

Drilling Campaign

The initial drilling campaign, to commence in May, will aim to infill and extend the maiden resource which already has two identified deposits (Dry Creek and West Tundra Flats) and a Resource base of 16.7Mt at 8.9% ZnEq (see Note below) including a high-grade component of 9.1Mt @ 12.9% ZnEq (see Note below) (refer ASX announcement 26 April 2017 regarding the maiden Mineral Resource).

This drilling is aimed to follow-up on drilling last done in the 1990s, which included

68.9m @ 4% Zn, 1.8% Pb, 58g/t Ag and 0.3g/t Au (DC98-60),

36.1m @ 6.2% Zn, 2.5% Pb, 183g/t Ag and 1g/t Au (DC98-40) and

12.5m @ 12.5% Zn, 5.5% Pb, 160g/t Ag and 1.1g/t Au (DC97-04).

(refer ASX Announcement dated 15 February 2016 "White Rock Minerals proposes to acquire VMS project in Alaska".)

Mobilisation

White Rock has engaged the services of the experienced, locally-based consultancy Northern Associates Inc. ("NAI") to be the Company's representative on the ground for the upcoming exploration program.

A contract for the exploration camp facilities has already been let, and preparations are underway to ready this for overland transport to the camp site.

The camp site, located proximal to the Red Mountain exploration program's focus around the Dry Creek and West Tundra Flats deposits, is to be accessed via ice road over winter in order to haul the necessary camp, drilling and other equipment in, ready for work to commence in May. This road, some 71 miles in length (114 kms), of which half is an existing and plowed winter road, and a further 20% established trails, has already been scouted, and all access permits received. The route traverses open low undulating terrain and three river crossings, heading west from the township of Delta Junction to the foothills of the Alaskan Range at Newman Creek where there is an already existing air strip.

Personnel and supply support for the camp and exploration program, once the thaw has occurred, will be via a 20 minute helicopter flight south from Fairbanks - Alaska's second largest city.

White Rock has also sought tenders for the drilling program and six responded, with a Preferred Contractor selected.

MD & CEO Matt Gill said "The Company is very excited about the potential for its globally significant high-grade Zinc VMS Project at Red Mountain, and the news flow that should come from a successful exploration program here.

Since acquiring the Red Mountain project in early 2016, we have expanded our strategic footprint 10-fold, to 143km2, and have also released a maiden Mineral Resource that immediately placed the Red Mountain Project in the top quartile of undeveloped high-grade VMS (zinc, silver, gold) deposits globally. Importantly, the two deposits identified within the Company's extensive land holding immediately placed the Red Mountain zinc project as one of the highest grade and more significant deposits of any zinc company listed on the ASX and an important VMS asset within a global context.

Now it is time to get on the ground.

Our aim here is to further build on our geological knowledge of the mineralisation, increase confidence in the Resource base, expand the already globally significant Resources at the existing deposits and discover new deposits.

We will, in parallel with the drilling program, also be conducting on-ground geophysics and geochemistry, testing many of the 30 already identified exploration targets developed from historic shallow EM and historic surface geochemistry, and explore the system for VMS related gold potential. We plan to drill the best of these regional targets towards the end of this drilling campaign.

This is an exciting time for White Rock".

No New Information or Data

This announcement contains references to exploration results and Mineral Resource estimates, all of which have been cross-referenced to previous market announcements by the Company. The Company confirms that it is not aware of any new information or data that materially affects the information included in the relevant market announcements and in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates in the relevant market announcement continue to apply and have not materially changed.

About Red Mountain (as more fully set out in the ASX Announcement dated 15 February 2016)

- The Red Mountain Project is located in central Alaska, 100km south of Fairbanks, in the Bonnifield Mining District. The tenement package comprises 224 mining claims over a total area of 143km2.

- The Red Mountain Project contains polymetallic VMS mineralisation rich in zinc, silver and lead, with potential for significant gold and copper.

- Mineralisation occurs from surface and is open along strike and down-dip.

- White Rock used historical drilling to determine a maiden JORC 2012 Mineral Resource estimate for the Dry Creek and West Tundra Flats deposit (ASX Announcement 26th April 2017). The Inferred Mineral Resource contains an impressive base metal and precious metal content with 678,000t zinc, 286,000t lead, 53.5 million ounces silver and 352,000 ounces gold.

- Good preliminary metallurgical recoveries of >90% zinc, >75% lead, >80% gold, >70% silver and >70% copper.

- Previous drilling highlights (ASX Announcement 15th February 2016) include:

Dry Creek

o 4.6m @ 23.5% Zn, 531g/t Ag, 8.5% Pb, 1.5g/t Au & 1.0% Cu from 6.1m

o 5.5m @ 25.9% Zn, 346g/t Ag, 11.7% Pb, 2.5g/t Au & 0.9% Cu from 69.5m

o 7.1m @ 15.1% Zn, 334g/t Ag, 6.8% Pb, 0.9g/t Au & 0.3% Cu from39.1m

West Tundra Flats

o 1.3m @ 21.0% Zn, 796g/t Ag,9.2% Pb, 10.2g/t Au & 0.6% Cu from 58.6m

o 3.0m @ 7.3% Zn, 796g/t Ag, 4.3% Pb, 1.1g/t Au & 0.2% Cu from160.9m

o 1.7m @ 11.4% Zn, 372g/t Ag, 6.0% Pb, 1.7g/t Au & 0.2% Cu from 104.3m

- VMS deposits typically occur in clusters ("VMS camps"). Deposit sizes within camps typically follow a log normal distribution, and deposits within camps typically occur at regular spacing. The known deposits at Dry Creek and West Tundra Flats provide valuable information with which to vector and target additional new deposits within the Red Mountain camp.

- Interpretation of the geologic setting indicates conditions that enhance the prospectivity for gold-rich mineralisation within the VMS system at Red Mountain. Gold mineralisation is usually found at the top of VMS base metal deposits or adjacent in the overlying sediments. Gold bearing host rocks are commonly not enriched in base metals and consequently often missed during early exploration sampling. This provides an exciting opportunity for potential further discoveries at Red Mountain.

- White Rock sees significant discovery potential, given the lack of modern day exploration at Red Mountain. This is further enhanced by the very nature of VMS clustering in camps, and the potentially large areas over which these can occur.

Note: ZnEq = Zinc equivalent grades are estimated using long-term broker consensus estimates compiled by RFC Ambrian as at 20 March 2017 adjusted for recoveries from historical metallurgical test work and calculated with the formula: ZnEq =100 x [(Zn% x 2,206.7 x 0.9) + (Pb% x 1,922 x 0.75) + (Cu% x 6,274 x 0.70) + (Ag g/t x (19.68/31.1035) x 0.70) + (Au g/t x (1,227/31.1035) x 0.80)] / (2,206.7 x 0.9). White Rock is of the opinion that all elements included in the metal equivalent calculation have reasonable potential to be recovered and sold.

To view tables and figures, please visit:
http://abnnewswire.net/lnk/6792NM0N

Matt Gill (MD & CEO)
Phone: +61-3-5331-4644
Email: info@whiterockminerals.com.au

Or Shane Turner (Company Secretary)
Phone: +61-3-5331-4644
WWW: www.whiterockminerals.com.au

Rumble Resources Ltd (ASX:RTR) ("Rumble" or "the Company") is pleased to announce that it has signed binding option agreements to acquire tenements E51/1677 and M51/122 that form the Munarra Gully Cu-Au Project (with Ni - Co potential) ("Munarra Gully") some 50km NNE of the town of Cue within the Murchison Goldfields.

Highlights

Rumble is targetting a highly prospective ultramafic intrusion with significant copper gold mineralisation and elevated nickel- cobalt.

- White Rose Prospect - M51/122

o Current surface small scale gold mining has delineated wide zones of copper and gold in shallow oxide.

o Shallow historic RAB drilling has defined mineralisation over a width of at least 50m with the copper mineralisation open along strike and at depth with significant potential at depth for copper sulphide mineralisation

Exceptional copper-gold mineralisation defined at the White Rose Prospect with historic shallow RAB drilling results (see Note below) include:

o 40m @ 0.66% Cu, 4.85 g/t Au from surface to EOH.

-- Inc 8m @ 1.32% Cu, 22.75 g/t Au from 24m

o 34m @ 0.75% Cu, 0.46 g/t Au from surface to EOH.

o 20m @ 0.54% Cu, 1.52 g/t Au from surface to EOH.

- Grab sampling completed by Rumble and others identified consistent copper in weathered ultramafic rocks exposed in two small pits currently being mined for gold. Results (33 samples) include:

o Average of 0.68% Cu (all 33 samples)
-- Up to 2.1% Cu.

o Au to 1.9 g/t, Ni to 0.37% and Co to 0.11%.

- Preliminary assessment of regional aeromagnetic data indicates a potential association with the copper mineralisation with magnetic "blowouts" along a ENE trending ultramafic intrusion.

o At least four "blowout" targets have been identified with approximately 8km of strike potential untested (for Cu-Ni-Co) ultramafic intrusion occurs within E51/1677 (100km2).

- Previous exploration of the Munarra Gully Project was for gold with no systematic exploration for Cu - Ni - Co with only select copper assays completed with the historic drilling.

- Rumble will commission a ground TEM survey in March over the White Rose Prospect to aid in delineating semi to massive copper and/or nickel sulphides conductors associated with the ultramafic intrusion.

- Rumble to drill test these first order targets in April.

- Surface geochemistry is planned in March to cover "blowout" targets.

Rumble has been implementing a clear strategy to proactively identify and review exploration opportunities that complement the Company's flagship Braeside High Grade Zinc-Lead project and that must pass a critical review by Rumble's technical director Brett Keilor.

The Munarra Gully Project has met these stringent criteria and will provide shareholders with another near-term opportunity to find a world class base and precious metal deposit, with drilling of identified targets to be scheduled in April 2018.

Project Exploration Status

The Munarra Gully project comprises of two tenements, E51/1677 (97.5km2) and M51/122 (111 ha). Previous exploration has focused generally on gold with shallow RAB and RC drilling on both tenements.

White Rose - M51/122

No official gold production is known however during the 1980's an extensive alluvial gold operation covered most of M51/122 with a reported production of "12,300t of surface alluvium producing 234 oz of gold" (refer JORC table for Open File reference). During the 1980's and 1990's exploration including drilling was conducted over the general area (partly including M51/122). The drilling (RAB, auger and RC) was shallow with the focus on defining shallow oxide gold resources. RAB drilling was generally 40m or less (angled) and the RC drilling was up to 100m (angled). Composite (4m) RAB assays returned wide zones of low to moderate grade copper (in oxide) which was partly associated with lower grade oxide gold within weathered ultramafic (talc-chlorite-tremolite) intrusive rocks. In general, only minor Cu assays were completed.

Historic RAB drilling intercepts (4m composites) from the area near the two small open cuts include (see image 2 in link below):

- 40m @ 0.66% Cu, 4.85 g/t Au, surface to EOH.
o Includes 8m @ 1.32% Cu , 22.75 g/t Au from 24m

- 34m @ 0.75% Cu, 0.46 g/t Au, surface to EOH.

- 20m @ 0.54% Cu, 1.52 g/t Au, surface to EOH.

Over the last 8 to 10years, the current owner established a small gold plant (ball mill and Knelson concentrator) to process shallow saprolitic (oxide) gold mineralisation defined by the previous RAB drilling. Although there are no official production records, there is approximately 1000t of tailings. The owner developed two small open cuts (down to 20m) which exposed a weathered (nontronite-talc saprolite) ultramafic intrusion at least 50m in width.

The ultramafic unit did not surface and was covered by alluvium and hardpan which masked the copper anomalism.

Previous exploration within E51/1677 focused primarily on gold exploration with wide spaced RAB drilling assaying only for gold and arsenic. To the west of E51/1677, an area of felsic volcanics attracted extensive Cu, Zn, Pb, Ag, Au exploration.

With the exposure of the copper bearing ultramafic unit at the White Rose Prospect by the recent small scale mining, the potential for disseminated to massive copper +/- nickel sulphide mineralisation is high as the ultramafic unit can be traced magnetically over a strike of at least 8km

Field inspection of the ultramafic intrusion along the inferred magnetic position (see image 3 in link below) indicates it is mostly under cover and where exposed, is significantly weathered.

Although subject to confirmation by drilling, the copper bearing ultramafic intrusion is closely associated with magnetic "blowouts" - see image 3 in link below - and appears to be slightly adjacent (lies to the north) to the main magnetic unit. Within E51/1677, at least four (4) "blowout" targets can be inferred and a preliminary review of Open File data indicates no systematic copper - nickel exploration has been completed over these targets.

Exploration Potential

Rumble considers the Munarra Gully Project as having high potential for economic copper mineralisation with nickel and gold associated with an extensive ultramafic intrusion striking over 8km. No systematic exploration has been completed over the proposed "blowout" targets.

At the White Rose Prospect, some 250 m of prospective ultramafic intrusion strike with strong copper and gold has been confirmed and the mineralisation is completely open to the west and at depth.

Proposed Exploration

Rumble plans to completed ground TEM (transient electromagnetic) traverses over the White Rose copper bearing ultramafic to aid in delineating conductors for deeper RC drilling. Within E51/1677, surface geochemistry is planned to test the "blowout" targets.

Planned Exploration includes:

- Ground TEM on M51-122 over the White Rose Ultramafic and extensions.
o Planned for March 2018.

- RC drilling of conductors/ultramafic - White Rose Prospect.
o Planned for April 2018.

- Surface Geochemistry over the "Blowout" targets in E51/1677.
o Subject to regolith and cover, programme may be maglag or auger.
o Planned for March 2018

Key Commercial Terms of the Option Agreements

Rumble has signed binding option agreements for E51/1677 and M51/122.

1. M51/122 Terms

Rumble has signed a binding option agreement with Radman Mining Pty Ltd and agreed to pay A$30,000 in cash and $30,000 in RTR ordinary shares (calculated using 5 day VWAP) to secure a 12-month exclusivity period to finalise due diligence.

If Rumble elects to exercise the option within the 12-month exclusivity period, Rumble agrees to enter a joint venture agreement to acquire up to 100% of the title and interest in M51/122 based on the below terms:

a. Rumble to pay $50,000 Cash and $50,000 RTR ordinary shares within 30 days from the joint venture agreement.

b. Rumble to make payment of $50,000 Cash and $50,000 RTR ordinary shares within 12 months from the joint venture agreement to earn 80% on the mineral rights excluding gold.

c. RTR guarantees the statutory annual expenditure.

d. Rumble has the option to acquire 80% of the gold mineral rights by paying A$500,000 in RTR shares, cash or a mixture of both at any time within 5 years of the joint venture agreement.

e. Rumble has the option to acquire the remaining 20% of all mineral rights by paying A$1,000,000 in cash at any time after acquiring 80% of mineral rights.

f. Radman Mining Pty Ltd is free carried to decision to mine.

g. Following a decision to mine, Rumble will pay a one off cash royalty of $1,500,000.

2. E51/1677 Terms

Rumble has signed a binding option agreement with Marjorie Ann Molloy and agreed to pay A$20,000 in cash and $20,000 in RTR ordinary shares (calculated using 5 day VWAP) to secure a 12-month exclusivity period to finalise due diligence.

If Rumble elects to exercise the option within the 12-month exclusivity period, Rumble agrees to enter a joint venture agreement to acquire up to 80% of the title and interest in E51/1677 based on the below terms:

a. Rumble to pay $75,000 Cash and $75,000 RTR ordinary shares within 30 days from the joint venture agreement.

b. Rumble to make payment of $25,000 Cash and $25,000 RTR ordinary shares within 12 months from the joint venture agreement to earn 80% on all mineral rights.

c. RTR guarantees the statutory annual expenditure.

d. Marjorie Ann Molloy is free carried to BFS.

e. Following the completion of a BFS and decision to mine, Marjorie Ann Molloy can either elect to contribute to ongoing project development or dilute to a 1% NSR.

Note: RAB results are composites and only indicative of grade and width

To view images, please visit:
http://abnnewswire.net/lnk/7N2NI644

Shane Sikora
Managing Director
Email: enquiries@rumbleresources.com.au
Phone: +61-8-6555-3980
Website: www.rumbleresources.com.au

OtherLevels Holdings Limited (ASX:OLV) ("OtherLevels") would like to clarify the announcement released today in respect of a A$2.25m multi-year agreement.

The baseline value of A$2.25m represents the contracted value over the 4 and a half year term. The payment will be received in 5 annual payments over the course of the contract, the first of which, representing A$580,000 will be received this quarter.

Media Enquiries
E: media@otherlevels.com
WWW: www.otherlevels.com

Speedcast International Limited (ASX:SDA), the world's most trusted provider of remote communication and IT solutions, today announced Full Year 2017 results, with revenue of US$514.2 million, a 136% increase over 2016, and corresponding EBITDA growth of 195%.

Financial highlights

- Total revenue of US$514.2M and EBITDA of US$122.6M in 2017

- Triple-digit year-on-year revenue growth of 136% and EBITDA growth of 195%

- EBITDA margin surged to 23.8% (FY16: 19.0%) reflecting the impact of cost synergies from the integration of Harris CapRock and operational leverage from increased scale

- 2017 includes two months of UltiSat contribution, a transaction completed on 1 November 2017. Revenues of US$14.1M and EBITDA of US$2.4M are included in the Speedcast Full Year 2017 results.

- Excluding UltiSat, Speedcast delivered US$500M in revenues and US$120.2M in EBITDA

- Final dividend of AU4.80cts per share, bringing 2017 total dividend to AU7.20cts per share, a 75% year-on-year increase in the overall dividend payment

Operational Highlights

- With the acquisition of Harris Caprock in January 2017, Speedcast provides service to approximately 70% of the cruise ships around the world, serving the two top global cruise fleets in addition to multiple smaller fleets

- Speedcast Energy revenues stabilised in 2017 as Energy companies continued to rely on Speedcast's communication solutions for their sites that remain in operation. During the year, our customers started planning for scalability as they await the sector's upswing in the next 12 to 18 months.

- In 2017 Speedcast Maritime revenues saw 18% growth as over 650 new VSAT services were activated for Commercial Maritime customers

- Enterprise and Emerging Markets grew slightly thanks to contributions from the Harris CapRock acquisition. NBN revenues expected in 2017 have been pushed to 2018.

- On November 1, 2017, Speedcast completed the acquisition of UltiSat which positions the Group well in the Government segment as military budgets are expected to grow globally

"2017 was a transformative year for Speedcast during which we firmly established our leadership position in the industry and built a unique global platform, with a stronger ability to win business," said Pierre-Jean Beylier, Speedcast CEO. "Our 2017 results demonstrate the benefits of our scale and the synergies derived from the acquisition of Harris CapRock. Speedcast's leadership in the key verticals we serve positions the company well for good financial performance in 2018. We will continue to focus on customer satisfaction, on innovation in all that we do, and on our people, who are our biggest asset."

Speedcast is also announcing that CFO Ian Baldwin will be leaving Speedcast at the end of the month for family reasons and will be pursuing a new opportunity. Ian joined the company shortly after the IPO in 2014 and during his tenure helped lead the group through significant growth, including the acquisition and integration of 10 companies. Speedcast is actively recruiting a new CFO with the right experience and leadership to drive the company through its next phase of growth. "I want to thank Ian for his contribution to the growth of Speedcast over the past three years and wish him all the best in the next chapter of his career," said Pierre-Jean Beylier, Speedcast CEO.

To view FY17 year end Financial Report, please visit:
http://abnnewswire.net/lnk/77L934G3

To view FY2017 results Presentation, please visit:
http://abnnewswire.net/lnk/MSLQ4W45

Media Contact:

Toni Lee Rudnicki
Vice President, Global Marketing
Speedcast International Ltd
E: tonilee.rudnicki@speedcast.com
T: +1-832-668-2634

Altech Chemicals Limited (Altech/the Company) (ASX:ATC) (FRA:A3Y) is pleased to announce that it has lodged a new provisional patent application with the Australian Patent Office (IP Australia), which incorporates the finished product HPA technology developed by it for its high purity alumina (HPA) project.

Highlights

- Provisional patent application lodged with the Australian Patent Office

- Incorporates finished product technology

- Global Intellectual Property search completed

o Altech's kaolin to HPA HCL processing route is unique

o There is no risk of patent infringement by Altech

- Altech's patent applications afford international protection for its HPA production method

The new patent application expands on a previously lodged patent application titled 'A Method for the Preparation of Alumina', which was filed by Altech in October 2014. The existing patent application describes Altech's method of preparing alumina from aluminous material, including kaolin. The new patent application incorporates various refinements made to the Company's HPA processing route during project due diligence, and incorporates the Company's latest invention, the flexible finished product line that is capable of producing HPA product for both the synthetic sapphire industry (high density pellets) and HPA for the lithium-ion battery industry (powder at sub-micron particle size).

The new patent application covers the following steps:

1. treating aluminous material to reduce particle size and increase the alumina content;

2. calcining the aluminous material;

3. leaching the aluminous material with hydrochloric acid;

4. solid liquid separation to provide a pregnant liquor;

5. crystallising aluminium chloride hexahydrate by adding hydrogen chloride gas;

6. precipitating and separation of aluminium chloride hexahydrate;

7. dissolving the aluminium chloride hexahydrate in water and repeating the crystallisation process;

8. roasting and calcining aluminium chloride hexahydrate to provide alumina; and

9. finishing alumina in either a high density bead or fine alumina powder

In addition, Altech is pleased to report that as part of project due diligence initiated by KfW IPEX-Bank, a global freedom to operate search was conducted to confirm that the Company will be free to produce, market, sell or otherwise distribute HPA manufactured by its unique process. The search involve the detailed review of existing alumina manufacturing patents and was conducted by Wrays Patent and Trade Mark Attorneys (Wrays), a highly regarded Australian firm specialising in patent and trade mark law.

The search was conducted across a database covering over 100 patent authorities containing over 60 million patent records. It involved identifying all patents or patent applications in the field of alumina preparation and all patents and patent applications covered by the World Intellectual Property Organisation. The search covered key market countries and areas such as Australia, People's Republic of China, Canada, Federal Republic of Germany, Europe, United Kingdom of Great Britain and Northern Ireland, Japan, Republic of India, Korea, Russian Federation, Taiwan, United States of America and Malaysia.

The results of the global search confirmed Altech's unique manufacturing process (Intellectual Property). Wrays did not identify any patent or patent application that could assert to prevent the production of HPA by Altech using its unique process in Malaysia, nor prevent the marketing, selling or distributing its HPA, or products containing its HPA, globally.

The search confirmed Altech's view that its IP for producing HPA from kaolin/aluminous material using its hydrochloric acid-based processing technology is unique, and that any other party that employs a similar process to produce HPA would most likely be in breach of Altech's patent applications.

Iggy Tan
Managing Director
Altech Chemicals Limited
Tel: +61-8-6168-1555
Email: info@altechchemicals.com 

Shane Volk
Company Secretary
Altech Chemicals Limited
Tel: +61-8-6168-1555
Email: info@altechchemicals.com

Investor Relations (Europe)
Kai Hoffmann
Soar Financial Partners
Tel: +49-69-175-548320
Email: hoffmann@soarfinancial.com

Collaborate Corporation Limited (ASX:CL8) (Collaborate or the Company) is pleased to present its Appendix 4D and Interim Financial Report for the period ending 31 December 2017.

Collaborate Corporation continued to capitalise on its unique strategic advantages in the first half of the 2018 financial year (H1 FY18) delivering a 52% increase in revenue for the period to 31 December 2017, a strong improvement on the 34% growth achieved in the prior year period ending 31 December 2016 (PYP).

Most of the revenue increase was attributable to the DriveMyCar business unit which benefited from key product launches in the latter part of H1 FY18, including RACV DriveMyCar and Subaru XV vehicles in September 2017 and Flexible Rideshare Rentals for Uber drivers in December 2017. Momentum accelerated in the second quarter of H1 FY18 with cash receipts increasing 42% in the December 2017 Quarter compared to the September 2017 Quarter. The new B2B sharing platform, Mobilise, also launched in late October 2017.

The launch of each of these new initiatives was made possible by funding provided by the $1 million strategic investment from RACV and 100% exercise of the CL8 listed options in April 2017. Due to the significant investment made in new products, which provide the potential for increased revenue in subsequent periods, the net loss from ordinary activities increased compared to the PYP. Much of the new investment was for the recruitment of management personnel and technology development to support the ongoing extension of the Collaborate Technology platform and the growth of the businesses. In addition, there were share based payment expenses relating to the issue of options, which is an accounting entry only and does not reflect any historic or future cash outflow. Excluding both of these costs, the net loss from ordinary activities would have declined by 6%. During H1 FY18 Collaborate improved the financial performance of its existing businesses and also deployed available funds to invest in and foster future revenue opportunities.

In accordance with Listing Rule 4.2A.3, the Interim Financial Report for the six months ended 31 December 2017 and Appendix 4D - Half Year Report of Collaborate Corporation Ltd (ASX:CL8) follow this announcement. This information is to be read in conjunction with the annual report for the year ended 30 June 2017.

To view the report, please visit:
http://abnnewswire.net/lnk/2U70Q7B5

Collaborate Corporation Limited
Tel: +61-2-8889-3641
E: shareholder@collaboratecorp.com 
W: www.collaboratecorp.com

DroneShield Ltd (ASX:DRO) (OTCMKTS:DRSHF) ("DroneShield" or the "Company") is pleased to notify the market of the following statement by The Queensland Police Service (QPS), made today:

The QPS is pleased to announce that DroneShield Ltd (ASX:DRO) ("DroneShield" or the "Company") will provide multiple units of its DroneGunTM product to be utilised by Queensland Police Service during the XXI Commonwealth Games in Queensland in April 2018.

Given the developments in unmanned technologies, and the trends in the nefarious uses of such technologies overseas, security agencies and militaries worldwide are faced with the need to provide aerial security at all high profile events, in addition to conventional security. The Commonwealth Games event is a pre-eminent gathering of approximately 6,600 athletes from approximately 70 countries. Consequently, security agencies are providing the highest level of security at the event.

The QPS is pleased that DroneShield DroneGunsTM will be used as part of counter drone protection during the Games. The use of this equipment by the QPS is an indication of the Company's successful track record of protecting mass events, including the most recent 2017 IRONMAN World Championship and the Boston Marathon for three years running.

Importantly, the deployment of DroneGunsTM showcases the capability of the domestic Australian defence industry. In protecting the community at the April event, the QPS is able to rely on a product developed by an Australian company, that is dedicated to developing a more substantial relationship with a range of Australian federal and state police and security agencies.

Oleg Vornik
CEO and Managing Director
Email: oleg.vornik@droneshield.com
Tel: +61-2-9995-7280

Australian Securities and Frankfurt Stock Exchange cross listed iSignthis Ltd (ASX:ISX) (FRA:TA8), the global leader in RegTech for identity verification and transactional banking/payments, is pleased to provide the following update for the half year ended 31st December 2017.

First Half Highlights:

- Revenues for 1HFY18 outperformed expectations, driven by stronger than expected platform usage from existing customers, especially new merchants activated in the December quarter,

- Settlement processing for customers commenced in the second half with growth in GTPV exceeding management expectations over this period,

- Total audited revenue for the 1H FY18 of A$827k (versus 1H FY17 of A$308k),

- Successfully completed a share placement to institutional investors raising $6.5m at $0.19 per share,

- iSignthis eMoney Ltd is now a Principal Member of the world's leading card schemes: Visa Inc (NYSE:V), Mastercard (NYSE:MA), as well as JCB International.

Subsequent to the end of the first half the partnership with Worldline, to provide payment settlement services to EU based customers, went "live" in January. Contracting of the first 4 major merchants has since been announced on the 26th February 2018.

Operational Trading Outlook:

- Growth in settlement processing continues to exceed expectations,

- The company guidance is for revenue growth in the March quarter to be at least 50% higher than the December quarter (previously at least 30%) based on actual transactions to 23rd Feb,

- Quarterly settlement revenue growth in the March quarter has exceeded overall revenue growth rates, however Tx volumes from one merchant (processing customer only) have been adversely affected due to volatility in the cryptocurrency markets,

- Settlement revenues now make up over 65% of our revenue by vertical and will be the primary driver of revenues going forward,

- The company updated the annualised GTPV book value to be in excess of $400m from the previously reported $100m in its announcement on the 26th February 2018.

BUSINESS UPDATE

The Company is pleased with the continual growth quarter on quarter and the generation of revenue as existing merchant settlement volumes increase. Our pipeline of new merchants remains strong and we will continue to update the market regarding material changes as they occur. The company will provide a more detailed update following the March quarter. The Company is now exploring other eMoney services which it may offer to market under the license conditions afforded to it by its EEA Monetary Financial Institution authorisation.

FUTURE REPORTING

The Company has previously advised that it's subsidiary company iSignthis eMoney Ltd, trading as ISXPay, has been granted an eMoney Institution (EMI) License #115.1.3.17 by the Central Bank of Cyprus (CBC). This allows the Company to operate as a full transactional, deposit taking eMoney Monetary Financial Institution (MFI) in the European Economic Area (EEA).

The eMoney MFI license requires the Company to report to the CBC on a monthly basis, as well as providing specific reports on a half yearly and annual basis. The annual reporting includes audited accounts and is based on the standard European timetable of reporting on a calendar year from January to December, as opposed to the July to June financial reporting year that is common place in Australia.

To assist with this report, and to avoid multiple audits, the Company will apply to ASIC to change it's reporting date to 31 December as opposed to 30 June, effective for the 2018 calendar year. This change is likely to be implemented in 2018 meaning that the Company's accounts will be audited 30 June 2018 as would normally be the case and we will follow with a second audit as at 31 December 2018, which will then comprise the results of the period from 1st July 2018 - 31st December 2018.

Future reporting will then be based on a half year review as at 30 June and a full year audit as at 31 December.

To view the report, please visit:
http://abnnewswire.net/lnk/0J3C6ME8

Media: contact@isignthis.com

Investor Relations
Chris Northwood
Activ8Capital
T: +61-458-809-177 
E: cnorthwood@activ8capital.com or investors@isignthis.com

Fluence Corporation Limited (ASX:FLC) (OTCMKTS:EMFGF) is pleased to announce its results for the 12-month period ended 31 December 2017 ("2017") - refer the accompanying ASX Appendix 4E. The Company ended 2017 with a contract revenue backlog of US$95 million. Revenues are expected to nearly double in 2018.

Multiple milestones achieved in 2017

During 2017, Fluence successfully undertook the merger of Emefcy and RWL Water, with all merger-related integration activities completed. This has enabled Fluence to expand the global reach and market opportunities for its key products: desalination, wastewater treatment and wastewater-to energy.

Notable successes include:

- Innovation drove new market opportunities, including the first SUBRE product contract awarded to upgrade a centralised wastewater treatment plant in Israel. SUBRE enables compliance with tighter nitrogen discharge rules without using hazardous chemicals, while also increasing plant capacity;

- The Company's Chinese subsidiary was incorporated and its manufacturing facility in Jiangsu Province is now operating. First production of MABR Modules was achieved in September 2017;

- Progress in China with the signing of a framework agreement with partner Jiangsu Jinzi Environmental Science and Technology Company. The agreement contemplates the delivery of six Containerized Smart Packaged wastewater treatment plants based on Fluence's MABR technology (C-MABR);

- Exclusive memorandum of understanding (MOU) signed with an African nation to design and construct an advanced water treatment plant;

- EUR1.5 million contract signed with VINCI Construction Grands Projects (France) to supply three NIROBOX(TM) containerized seawater desalination units for the island of Mayotte;

- US Virgin Islands MABR installation received approval from the US Environmental Protection Agency;

- US$1.7 million contract executed with Irotop S.A., a leading Ecuadorian fish processing company, to purify wastewater from its tuna and sardine processing and packing plants;

- Agreement executed with Stanford University to deploy, test and evaluate Fluence's MABR wastewater treatment technology at Stanford's Codiga Resource Recovery Center. The MABR demonstration unit will be commissioned in Q1 2018; and

- Awarded the "2018 Global Decentralized Water & Wastewater Treatment Company of the Year" by Frost and Sullivan who noted the key benefits of Fluence's modular, decentralised systems, such as lower operating cost, easier maintenance, and lower capital outlays.

Operating in markets with attractive fundamentals

Water scarcity is increasing due to global economic development and climate change. Communities are being challenged to come up with viable solutions to overcome this problem.

Current centralised water treatment plants present major challenges to address this scarcity issue as they tend to be landlocked, have aging infrastructure and increasingly cannot meet the demands for clean water. Moreover, such centralised water treatment plants cannot be expanded easily, and upgrades are costly.

In response to these challenges, investment is being made in alternative decentralised solutions to address capacity needs quickly and economically, and importantly meet growing regulatory requirements.

China

The rural wastewater treatment opportunity in China is estimated in the billions of dollars over the next five years. The Chinese Government's 13th five-year plan targets improved water quality nationwide by 2030, and mandates that local city officials improve sewage capacity and treatment. Currently only 10% of rural wastewater is treated - the five-year plan mandates an increase to 70%.

There is strong momentum building in China with several opportunities in advanced stages of negotiation and anticipated to be finalised in the first half of 2018.

Africa

Fluence continues to build a pipeline of new opportunities that are converting into new contracts.

Progress is being made in negotiating the terms of a formal contract for the previously announced exclusive MoU with an African nation to construct a large water treatment plant. Other key conditions to the project commencing, which are typical for projects of this nature, include regulatory approvals and completing financing arrangements. Subject to completing these preconditions, the project has the potential to generate revenues of more than US$100 million for the Company.

In addition, Fluence has submitted several tenders for the provision of desalination water treatment in South Africa.

South America

Fluence is experiencing rapid expansion in South America with US$6 million of new contracts awarded in Ecuador and Argentina during 2017, and the anticipated recommencement of activities under a contract in Venezuela worth US$18 million in 2018.

To meet this growing demand across South America, Fluence is constructing a new manufacturing facility in Argentina, which is scheduled to open in Q2 2018.

Europe

In Italy, Fluence is contracted to develop and build a wastewater-to-energy treatment plant for Avimecc, a poultry meat processing company. This southern Italian plant processes approximately 40,000 chickens per day with plans to increase capacity to 70,000. Avimecc expects to recoup the cost of the expanded operation through energy recovery and waste reduction within 5 years of plant operation.

Worldwide regulations regarding total nitrogen content in treated effluent are becoming increasingly stricter. As a result, the Company estimates the SUBRE market opportunity in Europe alone may be US$2 billion, with even larger market potential in the US and China.

North America

The deployment of an MABR demonstration unit at the Código Resource Recovery Center (CR2C) at Stanford University in California has been successfully achieved. This will serve as a demonstration plant and reference site to underpin US sales.

Positioned for substantial growth in 2018

Based on the Company's current backlog and pipeline of new tenders, revenue for 2018 is expected to be in the range of US$105 million to US$115 million. Visibility of forecasted 2018 revenues is high, with approximately 70% (US$75 million) covered by the current backlog expected to be recognized in 2018.

Reflecting the changing mix of contracts in 2018, Gross Profit is anticipated to be in the range of US$22 million to US$25 million. This reflects the lower gross profit margin during the construction phase of a large project in San Quintin Mexico.

Based on current backlog and pipeline, and consistent with historic experience, the Company anticipates bookings and revenue to be weighted to the latter part of the year. We continue to target the achievement of a positive EBITDA run rate in 2019.

To view the Preliminary Final Report, please visit:
http://abnnewswire.net/lnk/M81MTVQ9

Corporate: 
Henry Charrabé (USA)
Managing Director & CEO
E: hcharrabe@fluencecorp.com
P: +1-212-572-3766 

Richard Irving (USA)
Executive Chairman
E: rirving@fluencecorp.com
P: +1-408-382-9790 

Ross Kennedy (Australia)
Company Secretary & Advisor to the Board
E: rkennedy@fluencecorp.com
P: +61-409-524-442

Investors (Australia):
Ronn Bechler
Market Eye
E: ronn.bechler@marketeye.com.au
P: +61-400-009-774

Media (Australia):
Tristan Everett
Market Eye, Market Eye
E: tristan.everett@marketeye.com.au
P: +61-403-789-096 

Investors & media (USA):
Gary Dvorchak, CFA
The Blueshirt Group
E: gary@blueshirtgroup.com
P: +1-323-240-5796 (US) or +86-138-1079-1480 (China)

Prospect Resources Limited (ASX:PSC) ('Prospect' or 'the Company'), is pleased to announce that it has exercised its option to acquire the Good Days Lithium Project, which was first signed on 12th June 2017.

Prospect's flagship project is the Arcadia Lithium Project located on the outskirts of Harare in Zimbabwe. The Arcadia Lithium Project represents a globally significant hard rock lithium resource and has been aggressively developed focusing on near term production of petalite and spodumene concentrates.

The 8km2 Good Days lithium project is located in north eastern Zimbabwe and contains numerous mineralised pegmatites, including historical workings for spodumene and tantalite (amongst other minerals) at the Good Days and Jordywyitt mines. It is currently held by the Zimbabwean company Barrington Resources Pvt Ltd, who Prospect entered into an option agreement with in June 2017 to acquire a 70% direct interest in the project following a positive outcome from due diligence. The extension of this option agreement, until April 2018, allowed time for our team to regionally map and sample the remainder of the Good Days claims before a decision on whether to exercise the option agreement was made. With the positive changes occurring in Zimbabwe under the new Zimbabwe Government, Prospect elected to exercise the option early to give clarity to investors on the make up of our expanding lithium portfolio and to fast track exploration.

The project area is located approximately 30km east of the town of Mutoka in north eastern Zimbabwe and some 160km from the capital city, Harare, and consists of a swarm of Lithium-Caesium-Tantalum ('LCT') pegmatites which were historically worked for spodumene, beryl, tantalite, columbite, cassiterite, feldspar and lepidolite. Since the option agreement was first entered into in June, Prospect have drilled the known mineralised pegmatite zone to verify the historic geological model and undertaken two phases of soil sampling to identify other areas which may host economic lithium pegmatites. A total of 2,556 soil samples were collected from almost 51km of surveyed lines on the western extension to the previously identified Ford-Ntabeni lithium pegmatites swarm. These form a parallel zone to the Good Days pegmatite.

A total of 195 samples returned anomalous values; greater than the statistically determined threshold of 60ppm. 33 of these samples assayed greater then 100ppm, with a peak value of 8,531ppm. Three distinct 200m - 300m long anomalies have been defined on different pegmatites within the Ford-Ntabeni swarm.

In addition, the results of the 518 chip samples are equally encouraging. 24 of them have returned grades greater than 1% Li20, with three of them > 4%. These higher grades are from pegmatites within the Ford-Ntabeni and Good Days swarms.

The identification of anomalous lithium values in soil samples suggests that hard rock mineralisation may be present beneath the soil cover and increases the prospectivity of the Good Days project away from the site's historic workings. These latest results confirm the prospectivity of the greater area.

The discovery of further lithium mineralisation at the project would mean that the Good Days deposit would be a significant addition to Prospect Resource's strategic lithium resource base in Africa.

The Company intends to commence with a follow up exploration programme focusing on defining a JORC reportable Mineral Resource and generating material for metallurgical testwork. The next phase will consist of infill soil sampling followed by trenching, and where appropriate short hole percussion drilling.

Hugh Warner
Prospect Resources Ltd
Executive Chairman
T: +61-413-621-652

Harry Greaves
Prospect Resources Ltd
Executive Director
T: +263-772-144-669
WWW: www.prospectresources.com.au

Fluence Corporation Limited (ASX:FLC) (OTCMKTS:EMFGF) is pleased to announce the appointment of two senior executives to further strengthen the Company's executive leadership team as Fluence positions for substantial growth in 2018.

- Appointment of CFO with significant experience in growing global technology businesses

- Appointment of CMO to drive strategic distribution channels across multiple products

Chief Financial Officer - Francesco Fragasso CPA

Francesco Fragasso will join the Company as Chief Financial Officer on 2 April 2018. Most recently, Francesco was CFO at Desalitech, a reverse osmosis technology company based in Boston, MA. Prior to that, Francesco worked as CFO for Nuvera Fuel Cells, Inc. part of Hess Corporation Group, and previously spent more than 10 years in public accounting with Deloitte.

Francesco holds Bachelor's and Master's Degrees in Business and Economics, from Universita' Bocconi, Milan, Italy as well as an Executive MBA from Boston University School of Management, Boston, MA.

Commenting on Francesco's appointment as CFO, Fluence Managing Director and CEO Henry Charrabé said: "We are excited to have Francesco join our leadership team. He has significant international experience in providing the financial reporting and control systems appropriate to position global technology companies for strong and sustainable growth, as well as the business acumen and experience necessary for the CFO role at Fluence. We believe he will make an immediate positive impact on our operations.

"On behalf of the whole company, I want to acknowledge the important contribution from Bob Wowk, Fluence's inaugural CFO, particularly through the financial integration of the Emefcy and RWL Water merger. Having made significant progress on the buildout of the financial infrastructure and controls, Bob felt the timing is ideal for new financial leadership that can commit the necessary time and energy over the long-term towards Fluence's success. He will be assisting Francesco during an extended transition period. We wish him all the best in his future endeavors."

Chief Marketing Officer - Erik Arfalk

Erik Arfalk will join Fluence in March in the newly created role of Chief Marketing Officer, reporting directly to the Managing Director & CEO. He has significant experience heading marketing teams for global industrial companies, most recently as Vice President Marketing & Communications (USA) for Sweden headquartered Atlas Copco and, prior to that, for General Electric's Life Sciences division. Erik holds a Master of Science Degree in International Strategic Management, Lund University, Lund, Sweden.

Erik will be responsible for strategic marketing and communications across Fluence's global portfolio of water and wastewater treatment solutions. His focus will be on establishing new strategic distribution channels, developing competitive offering strategies for Fluence's products in different geographies, as well as leveraging existing distribution channels by expanding the product offering.

Commenting on Erik's appointment and the newly created CMO role, Mr Charrabé commented: "Erik is an experienced global marketing executive who has successfully led multinational and geographically dispersed teams. His skill set is a perfect fit for Fluence's extensive global operations as we look to execute our growth strategy and deliver a step change in our business over 2018 and beyond. We believe Erik will make an outstanding contribution to our marketing team to support even greater success as we grow."

Corporate: 
Henry Charrabé (USA)
Managing Director & CEO
E: hcharrabe@fluencecorp.com
P: +1-212-572-3766 

Richard Irving (USA)
Executive Chairman
E: rirving@fluencecorp.com
P: +1-408-382-9790 

Ross Kennedy (Australia)
Company Secretary & Advisor to the Board
E: rkennedy@fluencecorp.com
P: +61-409-524-442

Investors (Australia):
Ronn Bechler
Market Eye
E: ronn.bechler@marketeye.com.au
P: +61-400-009-774

Media (Australia):
Tristan Everett
Market Eye, Market Eye
E: tristan.everett@marketeye.com.au
P: +61-403-789-096 

Investors & media (USA):
Gary Dvorchak, CFA
The Blueshirt Group
E: gary@blueshirtgroup.com
P: +1-323-240-5796 (US) or +86-138-1079-1480 (China)